Cancer/testis Antigen 1B (CTAG1B) ELISA Kits

The protein encoded by CTAG1B is an antigen that is overexpressed in many cancers but that is also expressed in normal testis. Additionally we are shipping Cancer/testis Antigen 1B Antibodies (120) and and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
CTAG1B 1485 P78358
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top Cancer/testis Antigen 1B ELISA Kits at antibodies-online.com

Showing 1 out of 6 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Supplier Delivery Price Details
Human 0.059 ng/mL 0.15 ng/mL - 10 ng/mL 96 Tests Log in to see 13 to 16 Days
$736.84
Details

More ELISA Kits for Cancer/testis Antigen 1B Interaction Partners

Human Cancer/testis Antigen 1B (CTAG1B) interaction partners

  1. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin.

  2. A significant association was found between AKAP4 gene expression and metastasis (P-value: 0.045), expression of the CTAG1B (NY-ESO-1) gene was not observed in our cases.

  3. In 22 melanoma patients with stage III lymph node metastasis, overall survival was significantly higher in the XAGE-1b and NY-ESO-1 double-negative group than in the other groups.

  4. The present results indicate the strong humoral immune response against NY-ESO-1 in natural human T-cell leukemia virus type 1 infection, irrespective of the clinical status.

  5. some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers.

  6. High NY-ESO-1 expression is associated with Lung Cancer.

  7. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas.

  8. Data suggest that only a small fraction of HLA-A*02:01- (HA)-binding ESO peptides are immunogenic, namely those that have high peptide-binding strength and peptide/HA complex stability. This study involved comparison of in silico-predicted and observed cytotoxic T-lymphocyte recognition of tumor antigen epitopes in melanoma patients and transgenic/knockout mice. (ESO = tumor antigen NY-ESO-1)

  9. These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible.

  10. Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS).

  11. MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies

  12. These cells were used to target a human lung cancer line that expressed NY-ESO-1.

  13. regulation of NY-ESO-1 processing by the ubiquitin receptors Rpn10 and Rpn13 as a well as by the standard and immunoproteasome is governed by non-canonical ubiquitination on non-lysine sites.

  14. CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors.

  15. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%).

  16. High expression of NY-ESO-1 is associated with Triple-Negative Breast Cancer.

  17. NY-ESO-1 expression in melanoma was associated with tumor progression, including increased tumor thickness, and with reduced tumor infiltrating lymphocytes.

  18. NY-ESO-1 is expressed in esophageal adenocarcinomas, Barrett's metaplasia and normal tissues other than germ cells

  19. NY-ESO-1 cancer antigen expression has a role in immunotherapy in thyroid cancer

  20. primary autoantibodies against intracellular MM-specific tumor antigens SSX-2 and NY-ESO-1 are rare but functional in multiple myeloma patients after allogeneic stem cell transplantation

Cancer/testis Antigen 1B (CTAG1B) Antigen Profile

Antigen Summary

The protein encoded by this gene is an antigen that is overexpressed in many cancers but that is also expressed in normal testis. This gene is found in a duplicated region of the X-chromosome and therefore has a neighboring gene of identical sequence.

Gene names and symbols associated with CTAG1B

  • cancer/testis antigen 1B (CTAG1B) antibody
  • CT6.1 antibody
  • CTAG antibody
  • CTAG1 antibody
  • ESO1 antibody
  • LAGE-2 antibody
  • LAGE2B antibody
  • NY-ESO-1 antibody

Protein level used designations for CTAG1B

New York esophageal squamous cell carcinoma 1 , autoimmunogenic cancer/testis antigen NY-ESO-1 , cancer antigen 3 , cancer/testis antigen 1 , cancer/testis antigen 6.1 , l antigen family member 2

GENE ID SPECIES
1485 Homo sapiens
Selected quality suppliers for Cancer/testis Antigen 1B (CTAG1B) ELISA Kits
Did you look for something else?